Cryo-Save's new growth strategy accross AsiaPacific Region
Corporate Updates

Cryo-Save’s new growth strategy accross AsiaPacific Region

Views: 505

Cryo-Save Group, Europe’s largest stem cell company announced its plans to scale up its investments in its 100% subsidiary Cryo-Save India and Asia Pacific region to meet the emerging demands of these two high-growth markets. Cryo-Save Group will scale up its investment to 2 million Euros in the Asia Pac region with another 2 million earmarked for the India operations within a span of 36 months. The stem cells which are present in umbilical cord blood at birth have immense potential to speed up treatments for life-threatening illnesses, injuries and disabilities is a realization that has dawned upon many developing countries thus opening new vistas of business opportunities for Cryo-Save Group. Increase investments to enhance sales and marketing operations and focus on creating innovative propositions in selected areas for Asia Pac customers form a part of Cryo-Save’s new business plan. Rob Koremans, Group CEO, Cryo-Save said, “Our new business alignment is a reflection of the significant role India plays in the company’s growth strategy. Cryo-Save is valued for its strong leadership presence in over 38 countries, cutting edge technology and fully automated storage facility that helps us to meet our customer’s needs. We have excellent long termrelationships with our customers, including doctors and Government organizations across our European geographies. We are confident that our local marketing teams comprehend the diversity of Indian customers and continue to deliver sustained value”.  Speaking about the uniqueness of the Cryo-Save lab in India, Prof. Colin McGuckin, Scientific Director, Cryo-Save India and creator of ‘mini liver’ said, “Our lab in Bangalore adheres to GMP & highest international standards. I was very impressed by it and we would be looking at Bangalore lab to do some of our projects”. Armed with 20 years of experience in stem cells, Professor McGuckin is an opinion leader who has been called upon by governments and hospitals around the world. He firmly believes that the stem cells which are present in umbilical cord blood at birth have immense potential to speed up treatments for life-threatening illnesses, injuries and disabilities. Mr.V.R.Chandramouli, Managing Director, Cryo-Save India informed, “Women in India are slowly but steadily realizing the potential of banking their umbilical cord cells. It’s heartening to see this trend is omnipresent not only in metros but in other major cities of our country. Our endeavor like always has been to bring to the table a depth of expertise and experience in stem cell banking space and we plan to devise new marketing strategies to reach out effectively to our target audience”. Cryo-Save India, the 100% subsidiary of Cryo-Save group Cryo-Save India, with its corporate office in Bangalore, was recently set up with an investment of 1.8 Million Euros. The group company, Europe’s largest adult stem cell storage bank, has its operations in 38 countries across 3 continents. Cryo-Save India brings to the table a depth of expertise and experience in stem cell banking. Cryo-Save India will be the only company in India with its unique offering of dual-storage system and this will be available for the first time in the country. They are also the only company that does automatic processing to avoid manual intervention and contamination. The company will be offering the collection and storage of ADULT stem cells derived from cord blood. Theservices will be available across all metros and other cities. Stem cells are the natural repair kit of the human body. In the last 18 years more than 10000 patients have been treated with cord blood stem cells transplantations in over 150 countries. Umbilical cord blood stem cells have been used over the years in an increasing number of treatments including leukemia, myelodysplastic syndrome, lymphomas, red cell disorders and more. Currently stem cell research is being done for more than 85 diseases. Cryo-Save India is headquartered in Bangalore with a state-of-the art, one-of-its-kind, fully automated adult stem cell storage facility. The facility at Bangalore covers 10,000 sq ft with a storage capacity of 150,000 samples, expandable to 300,000 immediately.  About Cryo-Save GroupCryo-Save Group is Europe’s largest adult stem cell storage bank, with more than 100,000 samples stored. The Company was established in 2000, is headquartered in The Netherlands, and owns or has access to, operating laboratory and storage facilities in Belgium, Germany and Dubai. Cryo-Save’s services are available in 38 countries across three continents (Europe,Asia, and Africa). Cryo-Save is a founding member of the International Tissue Engineering Research Association (ITERA), an international forum of scientists and researchers specialized in stem cells and tissue repair. Together with 5 universities in Europe and the Fraunhofer Institute, Cryo-Save has been selected to conduct fundamental research in the field of cryopreservationtechniques for stem cells in an EU funded Framework Program called CRYSTAL. Cryo-Save is focused on the collection and storage of ADULT stem cells derived from cord blood. About Cryo-Save IndiaCryo-Save India is headquartered in Bangalore with a state-of-the art, one-of-its-kind, fully automated adult stem cell storage facility. The facility at Bangalore covers 10,000 sq ft with a storage capacity of 150,000 samples, expandable to 300,000 immediately.  Cryo-Save India will be the only company in India with its unique offering of dual-storage system and this will be available for the first time in the country. They are also the only company that does automatic processing to avoid manual intervention and contamination. The company will be offering the collection and storage of ADULT stem cells derived from cord blood. Theservices will be available across all metros and other cities.

Recommended from all portals

Latest News

To Top